Department of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Department of Nuclear Medicine, University Hospital, LMU Munich, 81377, Munich, Germany.
Eur Radiol. 2023 May;33(5):3416-3424. doi: 10.1007/s00330-023-09518-y. Epub 2023 Mar 25.
The recently proposed standardized reporting and data system for somatostatin receptor (SSTR)-targeted PET/CT SSTR-RADS 1.0 showed promising first results in the assessment of diagnosis and treatment planning with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET). This study aimed to determine the intra- and interreader agreement of SSTR-RADS 1.0.
SSTR-PET/CT scans of 100 patients were independently evaluated by 4 readers with different levels of expertise according to the SSTR-RADS 1.0 criteria at 2 time points within 6 weeks. For each scan, a maximum of five target lesions were freely chosen by each reader (not more than three lesions per organ) and stratified according to the SSTR-RADS 1.0 criteria. Overall scan score and binary decision on PRRT were assessed. Intra- and interreader agreement was determined using the intraclass correlation coefficient (ICC).
Interreader agreement using SSTR-RADS 1.0 for identical target lesions (ICC ≥ 0.91) and overall scan score (ICC ≥ 0.93) was excellent. The decision to state "functional imaging fulfills requirements for PRRT and qualifies patient as potential candidate for PRRT" also demonstrated excellent agreement among all readers (ICC ≥ 0.86). Intrareader agreement was excellent even among different experience levels when comparing target lesion-based scores (ICC ≥ 0.98), overall scan score (ICC ≥ 0.93), and decision for PRRT (ICC ≥ 0.88).
SSTR-RADS 1.0 represents a highly reproducible and accurate system for stratifying SSTR-targeted PET/CT scans with high intra- and interreader agreement. The system is a promising approach to standardize the diagnosis and treatment planning in NET patients.
• SSTR-RADS 1.0 offers high reproducibility and accuracy. • SSTR-RADS 1.0 is a promising method to standardize diagnosis and treatment planning for patients with NET.
最近提出的用于生长抑素受体(SSTR)靶向 PET/CT 的标准化报告和数据系统 SSTR-RADS 1.0 在评估神经内分泌肿瘤(NET)的肽受体放射性核素治疗(PRRT)的诊断和治疗计划方面取得了有希望的初步结果。本研究旨在确定 SSTR-RADS 1.0 的内部和读者间一致性。
在 6 周内的 2 个时间点,根据 SSTR-RADS 1.0 标准,由 4 位具有不同专业水平的读者对 100 例患者的 SSTR-PET/CT 扫描进行独立评估。对于每次扫描,每位读者最多自由选择 5 个靶病变(每个器官不超过 3 个病变),并根据 SSTR-RADS 1.0 标准分层。评估整体扫描评分和 PRRT 的二进制决策。使用组内相关系数(ICC)确定内部和读者间一致性。
使用 SSTR-RADS 1.0 对相同靶病变(ICC≥0.91)和整体扫描评分(ICC≥0.93)的读者间一致性极好。所有读者对“功能成像满足 PRRT 要求并使患者成为 PRRT 的潜在候选者”的决策也表现出极好的一致性(ICC≥0.86)。即使在比较基于靶病变评分、整体扫描评分和 PRRT 决策的不同经验水平时,读者内一致性也极好(ICC≥0.98、ICC≥0.93 和 ICC≥0.88)。
SSTR-RADS 1.0 是一种高度可重复和准确的系统,用于对 SSTR 靶向 PET/CT 扫描进行分层,具有高内部和读者间一致性。该系统是标准化 NET 患者诊断和治疗计划的有前途的方法。
• SSTR-RADS 1.0 提供了高度的可重复性和准确性。• SSTR-RADS 1.0 是一种标准化 NET 患者诊断和治疗计划的有前途的方法。